3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
91
Leukemia, Lymphocytic, Chronic, B-Cell
28
Myelodysplastic Syndromes
18
Recurrence
9
Lymphoma, Mantle-Cell
9
Leukemia, Biphenotypic, Acute
8
Burkitt Lymphoma
8
Waldenstrom Macroglobulinemia
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Hematologic Neoplasms
6
Lymphoma, Follicular
4
Myeloproliferative Disorders
3
Multiple Myeloma
3
Anemia, Refractory, with Excess of Blasts
3
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, B-Cell
2
Leukemia, Myeloid
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Blast Crisis
2
Venentoclax
1
Targeted Therapy
1
Sarcoma, Myeloid
1
Interventions
Cyclophosphamide
5
ibrutinib
4
fludarabine
4
pirtobrutinib
3
obinutuzumab
3
acalabrutinib
3
fludarabine phosphate
2
Rituximab
2
Mesna
2
venetoclax
1
ricolinostat
1
idelalisib
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Melphalan
1
Leukapheresis
1
Doxorubicin
1
Diet
1
Busulfan
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
venetoclax
×
90 days
×
Clear all
NCT04608318
2026-04-30
CLL17
German CLL Study Group
Phase 3
Active not recruiting
897 enrolled